Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled Atm function

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2464-2469

  Kamijo, Takehiko ^a   Van De Kamp, Esther ^a   Chong, Miriam J ^a   Zindy, Frederique ^a   Diehl, J Alan ^a   Sherr, Charles J ^a   McKinnon, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL SIZE; CELL VOLUME; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IONIZING RADIATION; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RADIOSENSITIVITY;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELLS, CULTURED; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; EMBRYO; FIBROBLASTS; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR PROTEINS; PHENOTYPE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0033562997     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
2. Giaccia, A. J., and Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12: 2973-2983, 1998.
3. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
4. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
5. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 566: 701-704, 1993.
6. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
7. Sedgwick, R. P., and Boder, E. Ataxia-telangiectasia. In: P. Vinken, G. Bruyn, and H. Klawans (eds.), Handbook of Clinical Neurology, pp. 347-423, New York: Elsevier, 1991.
8. Lavin, M. F., and Shiloh, Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol., 15: 177-202, 1997.
9. Rotman, G., and Shiloh, Y. ATM: from gene to function. Hum. Mol. Genet., 7: 1555-1563, 1998.
10. McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D., and Cole, M. D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell, 94: 363-374, 1998.
11. Grant, P. A., Schieltz, D., Pray-Grant, M. G., Yates, J. R., and Workman, J. L. The ATM-related cofactor Tra1 is a component of the purified SAGA complex. Mol. Cell, 2: 863-867, 1998.
12. Vassilev, A., Yamauchi, J., Kotani, T., Prives, C., Avantaggiati, L., Qin, J., and Nakatani, Y. The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol. Cell, 2, 868-875, 1998.
13. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (Washington, DC), 281: 1674-1677, 1998.
14. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (Washington, DC), 281: 1677-1679, 1998.
15. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91: 325-334, 1997.
16. Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., and Kastan, M. B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev., 11: 3471-3481, 1997.
17. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
18. Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F., Shiloh, Y., Crawley, J. N., Ried, T., Tagle, D., and Wynshaw-Boris, A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell, 86: 159-171, 1996.
19. Xu, Y., and Baltimore, D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev., 10: 2401-2410, 1996.
20. Wang, Y. A., Elson, A., and Leder, P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc. Natl. Acad. Sci. USA, 94: 14590-14595, 1997.
21. Westphal, C. H., Schmaltz, C., Rowan, S., Elson, A., Fisher, D. E., and Leder, P. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res., 57: 1664-1667, 1997.
22. Khanna, K. K., and Lavin, M. F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene, 8: 3307-3312, 1993.
23. Elson, A., Wang, Y., Daugherty, C. J., Morton, C. C., Zhou, F., Campos-Torres, J., and Leder, P. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. USA, 93: 13084-13089, 1996.
24. Westphal, C. H., Rowan, S., Schmaltz, C., Elson, A., Fisher, D. E., and Leder, P. Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Genet., 16: 397-401, 1997.
25. Lowe, S. W., and Ruley, H. E. Stabilization of the p53 tumor suppressor is induced by adenovirus-5 E1A and accompanies apoptosis. Genes Dev., 7: 535-545, 1993.
26. Hermeking, H., and Eick, D. Mediation of c-Myc-induced apoptosis by p53. Science (Washington, DC), 265: 2091-2093, 1994.
27. Lowe, S., Jacks, T., Housman, D., and Ruley, E. H. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA., 91: 2026-2030, 1994.
28. Wagner, A. J., Kokontis, J. M., and Hay, N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1. Genes Dev., 8: 2817-2830, 1994.
29. Zindy, F., Eischen, C. M., Randle, D., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev., 12: 2424-2433, 1998.
30. ARF tumor suppressor. Genes Dev., 12: 2434-2442, 1998.
31. Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev., 12: 2984-2991, 1998.
32. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
33. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-1NK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell, 92: 725-734, 1998.
34. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
35. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17: 5001-5014, 1998.
36. ARF. Cell, 91: 649-659, 1997.
37. Land, H., Parada, L. F., and Weinberg, R. A. Cellular oncogenes and multistep carcinogenesis. Science (Washington, DC), 222: 771-778, 1983.
38. Ruley, H. E. Adenovirus early region IA enables viral and cellular transforming genes to transform primary cells in culture. Nature (Lond.), 304: 602-606, 1983.
39. Herzog, K. H., Chong, M. J., Kapsetaki, M., Morgan, J. I., and McKinnon, P. J. Requirement for Atm in ionizing radiation-induced cell death in the development central nervous system. Science (Washington, DC), 280: 1089-1091, 1998.
40. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
41. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
42. INK4. Science (Washington, DC), 267: 249-252, 1995.
43. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol., 16: 859-867, 1996.
44. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA, 93: 13742-13747, 1996.
45. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene, 15: 203-211, 1997.
46. Westphal, C. H., Hoyes, K. P., Canman, C. E., Huang, X., Kastan, M. B., Hendry, J. H., and Leder, P. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res., 58: 5637-5639, 1998.
47. Shiloh, Y., Tabor, E., and Becker, Y. Colony-forming activity of ataxia-telangiectasia skin fibroblasts is an indicator of their early senescence and increased demand for growth factors. Exp. Cell Res., 140: 191-199, 1982.
48. Vaziri, H., West, M. D., Allsopp, R. C., Davison, T. S., Wu, Y-S., Arrowsmith, C. H., Poirer, G. G., and Benchimol, S. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J., 16: 6018-6033, 1997.
49. Vaziri, H., and Benchimol, S., From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Exp. Gerontol., 31: 295-301, 1996.
50. Blasco, M. A., Lee, H. W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., and Greider, C. W. Telomerase shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91: 25-34, 1997.
51. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
52. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
53. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 387: 296-299, 1997.
54. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
55. Honda, R., Tanaka, H., and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420: 25-27, 1997.
56. Roth, J., Dobbelstein, M., Freedman, D., Shenk, T., and Levine, A. J. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17: 554-564, 1998.
57. Cliby, W. A., Roberts, C. I., Cimprich, K. A., Stringer, C. M., Lamb, J. R., Schreiber, S. L., and Friend, S. H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J., 17: 159-169, 1998.
58. Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S-Y., Taya, Y., Prives, C., and Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev., 13: 152-157, 1999.